PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.08
D/E ratio at 50-90% of Drug Manufacturers - Specialty & Generic median of 0.11. Peter Lynch would verify if this conservative capital structure supports growth opportunities.
-10.64
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 0.21. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-3.46
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
9.74
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.55. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
0.63%
Intangibles less than half the Drug Manufacturers - Specialty & Generic median of 10.28%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.